SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$26.45

22 Apr
2024

0.180

OPEN

$26.52

0.69%

HIGH

$26.68

1,230,108

LOW

$26.27

TARGET
$31.707 19.9% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 112.5 xxx
DPS (cps) xxx N/A 98.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 23.8 xxx
Dividend Yield xxx N/A 3.7% xxx
Div Pay Ratio(%) xxx N/A 87.3% xxx

Dividend yield today if purchased 3 years ago: 2.84%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.89

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/03 - ex-div 43c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx145.8
DPS All xxxxxxxxxxxxxxx104.0
Sales/Revenue xxxxxxxxxxxxxxx7,964.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,643.2
Net Operating Cash Flow xxxxxxxxxxxxxxx1,471.0 M
Net Profit Margin xxxxxxxxxxxxxxx8.60 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx9.13 %
Return on Invested Capital xxxxxxxxxxxxxxx6.70 %
Return on Assets xxxxxxxxxxxxxxx5.14 %
Return on Equity xxxxxxxxxxxxxxx9.13 %
Return on Total Capital xxxxxxxxxxxxxxx7.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx601.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx347 M
Long Term Debt xxxxxxxxxxxxxxx2,754 M
Total Debt xxxxxxxxxxxxxxx3,100 M
Goodwill - Gross xxxxxxxxxxxxxxx7,336 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx798 M
Price To Book Value xxxxxxxxxxxxxxx2.16

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx497.0 M
Capex % of Sales xxxxxxxxxxxxxxx6.24 %
Cost of Goods Sold xxxxxxxxxxxxxxx5,851 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,294 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx176 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

21/02/2024

3

Neutral

$27.85

5.29%

Sonic Healthcare's December-half net profit after tax missed consensus' and Macquarie's forecasts by -16% due to higher than forecast depreciation, amortisation and net interest costs. Earnings (EBITDA) were in line.

The broker observes a fall in the company's organic EBTDA, suggesting it has way to go to meet FY24 guidance and will require a strong second-half skew.

EPS revisions fall -11% in FY24; -8% in FY25; and -6% in FY26.

Neutral rating retained, the broker spying downside risk. Target price falls to $27.85 from $29.80.

FORECAST
Macquarie forecasts a full year FY24 dividend of 106.00 cents and EPS of 106.00 cents.
Macquarie forecasts a full year FY25 dividend of 108.00 cents and EPS of 125.00 cents.

Citi

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SHL STOCK CHART